This study is for people with newly diagnosed multiple myeloma (NDMM), a type of cancer affecting plasma cells in the blood. The study compares two treatment methods. One method uses a combination of drugs, **Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd)**, followed by a special therapy called ciltacabtagene autoleucel (cilta-cel), which uses the patient’s own altered immune cells to fight cancer. The other method uses the same drug combination, followed by an **Autologous Stem Cell Transplant (ASCT)**, where a patient's own stem cells are used to replace diseased cells.

To join, you need to have measurable NDMM, be suitable for high-dose treatment, and meet certain health criteria. You cannot join if you've had certain previous treatments, recent vaccines, or have specific health issues.

• The study involves about 750 participants, divided into two groups.
• Participants will be randomly assigned to one of the two treatment methods.
• The study aims to see which method works better in stopping disease progression and improving health.